SOLICITATION NOTICE
B -- AQUA Analysis of Estrogen Coregulators in the Polish Case-Control Study
- Notice Date
- 8/17/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70142-MM
- Response Due
- 8/31/2007
- Archive Date
- 9/15/2007
- Description
- The National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Hormonal and Reproductive Epidemiology Branch (HREB), intends to procure on a sole-source basis with Yale University School of Medicine, 310 Cedar Street, PO Box 208023, New Haven, CT 06520 to perform Automated Quantitative Analysis (AQUA) of immunofluorescent stains using antibodies for estrogen receptor coregulators. Staining would be performed on tissue micrarrays (TMAs) prepared from invasive breast carcinomas collected in the Polish Breast Cancer Case-Control Study. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106 (b) (1). The North American Industry Classification System Code is 541380 and the business size standard is $11M. The Tissue Microarray (TMA) technique, which permits the analysis of hundreds of tissue samples simultaneously using just a few slides, is ideally suited for epidemiological studies. Yale University has successfully built TMAs for 1761 (842 cases in TMA1 and 919 in TMA2) invasive breast cancer tissues collected from the Polish Breast Cancer Study. The first set of TMAs (TMA1) has been stained for four markers (ER-??, ER-??, PR and HER2) using Automated Quantitative Analysis (AQUA?) analyses. This work demonstrated AQUA analyses of tumors represented in TMAs provide reliable, quantitative measures of immunofluorescent, which can be used to advance research on differences in cancer etiology based on stratification of tumors by marker expression. In a continuation of this on-going study Yale University School of Medicine shall: 1) Perform AQUA analysis of TMA1 containing tissue samples from 842 Polish breast cancers with two-fold redundancy (i.e. 1,684 cores) for SRC3/AIB1, NCOR1, and NCRO2/SMRT; and 2) Perform AQUA analysis of TMA2 containing tissue samples from 919 cases with three-fold redundancy (i.e. 2,757 cores) for SRC3/AIB1, NCOR1, NCRO2/SMRT and ER-??. These activities are required in order to: 1) identify molecular subtypes of breast cancer; 2) evaluate associations between tumor subtypes defined by marker expression and risk factors for breast cancer; and 3) evaluate associations between tumor subtypes defined by marker expression and survival and prognosis of breast cancer patients. Yale University is the only vendor known to the NCI Researcher that can perform the required AQUA analysis without the introduction of new variables in on-going research. The laboratory of Dr. David Rimm at Yale University Medical School is uniquely qualified to perform this work. Yale has successfully prepared TMAs of 1,761 invasive breast cancers collected from the Polish Breast Cancer Study and performed AQUA staining of five markers on a subset of TMAs from 842 cases under previous orders (MQ217406; MQ317189; MQ515652). The current request is the continuation and expansion of the previous effort for arrays of invasive breast cancer tissues. The AQUA staining of invasive breast tissues requires an experienced laboratory with strong pathology consultation because of the technical difficulties. Yale has pioneered and validated this state-of-the-art technology. In addition, Yale has constructed and cut the TMAs that will be stained under this procurement, and has demonstrated high quality data derived from tissue samples collected in the Polish Breast Cancer Study. In short, Yale possesses unique expertise and resources for staining TMAs using the AQUA system, which is critical for the success of our ongoing efforts to identify etiologically distinct subtypes of breast cancer. This is not a solicitation for competitive quotations. However, if any interested party believes it can meet the above requirement, they may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI contracting office by 1:00 PM EST on August 31, 2007. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Melissa Marino, Contract Specialist at marinome@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference NCI-70142-MM on all correspondence.
- Record
- SN01376214-W 20070819/070817220637 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |